Bone Biologics Corporation
BBLG
$1.16
-$0.05-4.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.17M | 2.15M | 2.14M | 2.05M | 2.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.24M | 4.06M | 4.29M | 4.35M | 4.22M |
| Operating Income | -3.24M | -4.06M | -4.29M | -4.35M | -4.22M |
| Income Before Tax | -3.11M | -3.95M | -4.22M | -4.26M | -4.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.11 | -3.95 | -4.22 | -4.26 | -4.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.11M | -3.95M | -4.22M | -4.26M | -4.11M |
| EBIT | -3.24M | -4.06M | -4.29M | -4.35M | -4.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.00 | -7.30 | -21.13 | -23.83 | -29.77 |
| Normalized Basic EPS | -2.50 | -4.56 | -6.34 | -8.02 | -11.74 |
| EPS Diluted | -4.00 | -7.30 | -21.13 | -23.83 | -29.77 |
| Normalized Diluted EPS | -2.50 | -4.56 | -6.34 | -8.02 | -11.74 |
| Average Basic Shares Outstanding | 4.69M | 3.30M | 1.79M | 1.43M | 1.01M |
| Average Diluted Shares Outstanding | 4.69M | 3.30M | 1.79M | 1.43M | 1.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |